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Background. MicroRNAs (miRNAs) are short non-coding RNAs that regulate differentiation and development in many
organisms and play an important role in cancer. Methodology/Principal Findings. Using a public database of mapped
retroviral insertion sites from various mouse models of cancer we demonstrate that MLV-derived retroviral inserts are enriched
in close proximity to mouse miRNA loci. Clustered inserts from cancer-associated regions (Common Integration Sites, CIS) have
a higher association with miRNAs than non-clustered inserts. Ten CIS-associated miRNA loci containing 22 miRNAs are located
within 10 kb of known CIS insertions. Only one CIS-associated miRNA locus overlaps a RefSeq protein-coding gene and six loci
are located more than 10 kb from any RefSeq gene. CIS-associated miRNAs on average are more conserved in vertebrates than
miRNAs associated with non-CIS inserts and their human homologs are also located in regions perturbed in cancer. In addition
we show that miRNA genes are enriched around promoter and/or terminator regions of RefSeq genes in both mouse and
human. Conclusions/Significance. We provide a list of ten miRNA loci potentially involved in the development of blood
cancer or brain tumors. There is independent experimental support from other studies for the involvement of miRNAs from at
least three CIS-associated miRNA loci in cancer development.
Citation: Makunin IV, Pheasant M, Simons C, Mattick JS (2007) Orthologous MicroRNA Genes Are Located in Cancer-Associated Genomic Regions in
Human and Mouse. PLoS ONE 2(11): e1133. doi:10.1371/journal.pone.0001133
INTRODUCTION
MicroRNAs (miRNAs) are short RNA molecules, ,22 nucleotides
long, capable of performing regulatory functions. In particular,
miRNAs can suppress translation by non-perfect pairing to 39
UTRs and/or cause degradation of mRNAs in the case of a perfect
match between the miRNA and target mRNA [1]. It seems that
miRNAs do not have any catalytic activity but rather act as
sequence-specific guides for associated protein complexes which
are responsible for translation suppression or degradation of
mRNA [2]. The number of known miRNAs is growing rapidly,
and hundreds of verified miRNAs are annotated in human,
mouse, and other organisms (miRBase, http://microrna.sanger.
ac.uk).
A range of observations point to a link between miRNAs and
cancer, which is not surprising given their central role in many
cellular and developmental processes (for reviews see [3–5]). A
large number of human and mouse miRNAs have also been
shown to be located in regions associated with cancer [6,7]. The
expression of various miRNAs is altered in cancer and miRNA
profiling can be used for precise cancer classification [8]. Ectopic
expression of the mir-17-19b cluster accelerates tumor formation in
mice and has been accordingly classified as a potential oncogene
[9].
Retroviruses, such as the murine leukemia virus (MLV), can
cause tumor formation in mammals. Proviral insertions may
activate proto-oncogenes or lead to inactivation of tumor
suppressor genes in the vicinity of the insertion sites. Retroviral
integration sites can be determined in animals with cancer using
inverse PCR or similar techniques, and mapped to the genome
sequence. Regions harboring multiple insertion sites in close
proximity to each other are the most obvious candidates for cause
of cancer development and are often named Common Integration
Sites (CISs). In general, candidates for tumor-suppressor genes or
proto-oncogenes are selected from protein-coding genes based on
proximity to CISs.
Numerous genome-wide screens have been undertaken in
mouse to identify genes involved in carcinogenesis, especially
hematopoietic tumors [10–18]. Data obtained from various
screens on different cancer models (including studies with
genetically modified mice) has been compiled into the Retroviral
Tagged Cancer Gene Database (RTCGD, http://rtcgd.ncifcrf.
gov) [19] which also provides annotations for the UCSC genome
browser [20]. In the RTCGD, the CISs are defined as regions
containing two inserts located within 20 kb, 3 inserts within 50 kb,
and four or more inserts within 100 kb in the same cancer model
(see FAQ section of RTCGD on http://rtcgd.ncifcrf.gov) (for
details see [17]).
However, some CISs do not map near any known or annotated
protein-coding sequence. It was shown that insertions of retro-
viruses in the vicinity of the mir-17-92 miRNA polycistron cause
tumor formation and increase miRNA expression, indicating that
retroviral mutagenesis can be a potent tool for discovery of
oncogenic miRNAs [21,22]. Considering the emerging regulatory
role of microRNAs in cell differentiation and cancer we analyzed
the association between publicly available retroviral integration
sites and known miRNA loci in the mouse genome. We found that
miRNA loci are significantly enriched in the vicinity of CISs which
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PLoS ONE | www.plosone.org 1 November 2007 | Issue 11 | e1133suggests that some of these miRNA loci may also be considered as
candidate proto-oncogenes or tumor-suppressor genes.
RESULTS
Murine miRNA loci associate with retroviral common
integration sites
We analyzed co-localization between mouse miRNAs and
retroviral integration sites determined from mice that developed
cancer. For this analysis we used the 363 miRNAs from the
miRNA registry (http://microrna.sanger.ac.uk) that have been
mapped to 381 locations within the well-assembled fraction of the
mouse genome (four miRNAs mapped to more than one location).
The locations correspond to the genomic positions of miRNA
precursor sequences. We used the RTCGD database containing
2373 retroviral integration sites within Common Integration Sites
(CIS inserts) and 3119 retroviral integration sites mapped outside
of CISs (non-CIS inserts). We excluded from our analysis
integration sites of Sleeping Beauty transposons because non-
CIS insertions of Sleeping Beauty are non-randomly distributed
among the chromosomes: chromosomes 1, 4, 6 and 15 harbor
more than half of all Sleeping Beauty non-CIS integration sites.
Using a local mirror of the UCSC genome browser we found
that CIS inserts are located within 5 kb of 17 murine miRNAs and
within 10 kb of 22 miRNAs. Examples of co-localization between
miRNAs and CIS inserts are shown in Fig. 1 and a full list of CIS-
associated miRNAs is given in Table 1. Further increasing the
distance (past 10 kb) did not result in a significant increase of
miRNA numbers associated with CIS inserts (Fig. 2) indicating
that the association between miRNAs and CIS inserts is maximal
at short distances.
We used a bootstrap simulation to estimate the statistical
significance of the co-localization between retroviral integration
sites and miRNAs (see Materials and Methods). Because some
miRNAs are clustered in the genome and hence distributed non-
uniformly, we grouped miRNAs into loci by adding 5, 10, 20 or
30 kb to each side of the miRNA location and combining the
overlapping regions. This grouping is necessary to maintain
clustered and tandemly repeated miRNAs as single units (loci)
during the bootstrap procedure. Regions of the same sizes were
randomly placed on the mouse genome and cases of overlap with
retroviral integration sites were counted. The number of miRNA
loci that are located 10 kb or less from CIS inserts is
approximately 5.5 times higher than that observed for randomly
placed loci, and the probability of obtaining such a number by
chance is estimated as 1.7610
25. The enrichment declines with
the length of the miRNA loci, and the probability of obtaining
a similar overlap between miRNA loci and CIS inserts by chance
is higher for longer distances (Table 2). The bootstrap data
indicate that the strongest association between miRNA loci and
CIS inserts is at short distances, up to 10 kb. In agreement with
this, the number of CIS retroviral inserts near to individual
miRNAs is also highly enriched at short distances, and the
enrichment declines with distance.
Non-CIS inserts are enriched in the vicinity of miRNA
loci
We analyzed the co-localization between miRNAs and retroviral
inserts mapped outside of CISs. These non-CIS inserts are non-
clustered retroviral integration sites obtained in cancer screens.
Their role (if any) in tumorigenesis is unclear and so these inserts
are generally omitted from analysis. Low saturation in some
cancer screens suggests that some non-CIS inserts might be
located in regions involved in tumorigenesis, but on the other hand
it is possible to speculate that some are just by-products of the
cancer screen.
Figure 1. Examples of co-localization between miRNAs and CIS
retroviral integration sites in the mouse genome. Each panel
represents 20 kb of genomic DNA. Blue triangles indicate retroviral
integration sites, red ticks represent miRNAs, black boxes and lines
show the position of spliced transcripts. (A) chr11:87,562,001–
87,582,000. (B) chrX:48,977,001–48,997,000. (C) chr14:113,914,001–
113,934,000. Genome assembly mm8.
doi:10.1371/journal.pone.0001133.g001
Figure 2. The number of miRNAs co-localized with retroviral
integration sites. Blue diamonds represent the number of miRNAs
located at the indicated distance or less from CIS inserts, and red
diamonds correspond to miRNAs located at the indicated distance or
less from non-CIS inserts. The trendline for miRNAs associated with non-
CIS inserts is shown as red dotted line.
doi:10.1371/journal.pone.0001133.g002
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PLoS ONE | www.plosone.org 2 November 2007 | Issue 11 | e1133Table 1. Retroviral CIS insertions within 10 kb of murine miRNAs.
..................................................................................................................................................
MiRNA Insertions
b Type
c RIS gene Expression
c Human cancer
mir-9-1 * PDGFB.H8255 [12] Brain tumor Rhbg Brain
mir-196b
a * 403_0_8 [17] myeloid Hoxa7/Hoxa9 BM
* M15-5S8 [10] B cell
* M35-5B3 [10] B cell
* M17-5B5-1 [10] B cell
* 45f23 [17] myeloid
* 443_0_8 [17] myeloid
* SL024-1 [18] myeloid
* 143_1 [17] T cell
* M35-5S2-1 [10] B cell
* M8-5S2-1 [10] B cell
mir-135a-1 Dkm4.24 [15] B cell Wdr82 N/D Lung, breast cancer
let-7g Dkm83.2 [15] B cell Wdr82 Thymus
mir-363 * 0249.HH76 [11] T cell Phf6 N/D Advanced ovarian
carcinoma
mir-92-2 * 0251.HH14 [11] T cell BM
mir-19b-2 * S5_5039B [16] B cell HeLa, Colon
mir-20b * y174-425s [13] Lymphoma
mir-106a * 0250.HH10 [11] T cell HeLa, BM
* S5_3196A [16] B cell
* 253.dKON006.05 [11] T cell
B3_4153A [16] B cell
mir-212 * T5_11746C1 [16] B cell Hic1/Dph1 Heart Hepatocellular
carcinoma, lung cancer
mir-132 * S5_7233D [16] B cell Frontal Cortex
* i142-4000p [13] Lymphoma
mir-22 * S3_049b [17] B cell 2010305C02Rik Skeletal Muscle
* S158_3_11_29 [17] myeloid
mir-142 160.dKON070.05 [11] T cell Supt4h2/Bzrap1 BM Prolymphocytic
leukemia, breast cancer
b153-600s [13] Lymphoma
B3_7230C1 [16] B cell
b114-600s [13] HS
* b156-570s [13] Lymphoma
* Dkm127.69 [15] B cell
* B119_3_1_1_16 [17] myeloid
* 583_3_5kb [17] N/D
mir-23b PDGFB.B42 [12] Brain tumor Fancc Heart Urothelial cancer
mir-27b N/D
mir-24-1 Placenta
mir-17 199.dKON049.01 [11] T cell Gpc5 HeLa Follicular lymphoma
mir-18 * B5_12171B1 [16] B cell HeLa, BM
mir-19a * Lnz25-3 [14] T cell HeLa, Colon
mir-20a HeLa, BM
mir-19b-1 HeLa, Colon
mir-92-1 BM
aNot all RISs are shown.
bReference in brackets, * less than 5 kb between insert and miRNA loci.
cN/D – not determined, BM – bone marrow, HS – histiocytic sarcoma.
doi:10.1371/journal.pone.0001133.t001
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PLoS ONE | www.plosone.org 3 November 2007 | Issue 11 | e1133The number of miRNA located at a given distance from non-
CIS inserts increases proportionally to the distance between the
miRNA and non-CIS insert (R
2=0.9396), whereas the number of
miRNAs associated with CIS inserts does not display such a strong
linear dependence (Fig. 2) (R
2=0.7831). The association of
miRNA with CIS inserts is better described by a logarithmic
trendline with R
2=0.945 (see Materials and Methods). The
bootstrap simulation showed a significant enrichment for miRNA
loci associated with non-CIS inserts, especially for distances less
than 5 kb (Table 3). The number of non-CIS retroviral integration
sites in the vicinity of miRNAs has a slightly higher enrichment
than the enrichment for miRNA loci. Close examination of
miRNA loci associated with non-CIS inserts revealed several loci
with two independent non-CIS inserts located very close to each
other. For example, among 13 miRNA loci (16 miRNAs) with
non-CIS inserts within 10 kb, ten loci have a single insert, and
three loci have two inserts. These closely located inserts were
isolated from different cancer models, which is why these inserts
were classified as non-CIS. We analyzed the distribution of
distances between non-CIS inserts in the genome. There is
significant increase in the number of non-CIS inserts located
within 3 kb of each other, whereas the number of non-CIS
insertions at longer distances is more or less uniform when
measured in 1 kb bins. A total of 332 out of 3119 inserts outside of
CISs are located within 3 kb of each other.
We removed all non-CIS inserts located within 3 kb of each
other and repeated the bootstrap analysis. Nevertheless, even
this dataset shows approximately two-fold enrichment for
miRNA loci associated with non-CIS inserts separated by 3 kb
or more (Table 4). The enrichment is similar for all distances
analyzed but the association at longer distances is statistically
more significant.
Based on this bootstrap analysis we conclude that miRNA loci
show the strongest association with CIS inserts at short distances
(less than 10 kb). At distances less than 10 kb the enrichment of
miRNA loci overlapping with CIS inserts is two times higher than
the enrichment of miRNA loci overlapping with non-CIS inserts.
At longer distances, such as 30 kb, miRNA loci show a similar
association both with CIS and non-CIS inserts.
MicroRNA loci are enriched around starts and ends
of protein-coding genes
It is known that integration of murine leukemia viruses and MLV-
derived vectors preferentially occurs around promoter regions
Table 2. Bootstrap analysis for co-localization between miRNAs and CIS inserts.
..................................................................................................................................................
Distance, Kb
MiRNA
loci, #
Observed
a # loci
# inserts
Enrichment,
fold
b Bootstrap (10
7iterations)
P
c Max
d
5 245 7 6.3 0.00014 10
29 11.6 0.0034 118
10 237 10 5.5 0.000017 13
44 9.3 0.0031 122
20 233 11 3.7 0.00021 15
65 7.1 0.0044 166
30 228 11 2.8 0.0019 18
77 6.1 0.0038 195
aNumber of miRNA loci overlapping CIS inserts in the mouse genome.
bRatio between observed and bootstrap average.
cProbability of obtaining at least the observed number of miRNA loci overlapping CIS inserts (upper line) or the probability of obtaining at least that number of CIS
inserts overlapping miRNA loci (lower line) in bootstrap procedure.
dMaximum number of miRNA loci overlapping with CIS inserts (upper line) or maximum number of CIS inserts overlapping miRNA loci (lower line) obtained in the
bootstrap procedure.
doi:10.1371/journal.pone.0001133.t002
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Table 3. Bootstrap analysis for co-localization between miRNAs and all non-CIS retroviral integration sites.
..................................................................................................................................................
Distance, Kb
MiRNA
loci, #
Observed
# loci
# inserts Enrichment, Fold
Bootstrap (10
7 iterations)
PM a x
5 245 10 3.3 0.0011 15
12 3.7 0.00044 19
10 237 13 2.3 0.0054 20
16 2.6 0.0018 26
20 233 25 2.3 0.000076 30
30 2.5 0.000058 38
30 228 31 2.0 0.00018 38
40 2.4 0.00001 47
See Table 2 for description of the columns.
doi:10.1371/journal.pone.0001133.t003
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PLoS ONE | www.plosone.org 4 November 2007 | Issue 11 | e1133[23]. Indeed, out of 3119 non-CIS retroviral sites from RTCGD
database, 1190 (38%) are located within 5 kb of annotated
transcription start sites of RefSeq genes (occupying ,6.8% of the
genome). This represents more than 5-fold enrichment, higher
than the enrichment of non-CIS insertions around miRNA loci
(Tables 3 and 4). Out of 2373 CIS inserts, 989 (42%) are located
within 5 kb from annotated transcription start sites of RefSeq
genes.
We analyzed the distribution of miRNA loci in the mouse
genome with respect to RefSeq genes. Out of 381 miRNA
locations, 155 (41%) overlap RefSeq Genes which occupy 32% of
the mouse genome. Among these, 22 (6%) miRNAs overlap exons
(2% of the genome), and 133 (35%) are located in introns (30% of
the genome). Somewhat surprisingly, we found that miRNAs are
enriched close to the start or the end of genes: 69 (18%) and 72
(19%) miRNAs are located within 5 kb of RefSeq gene
transcription start or end sites, respectively (,2.6 and ,2.8 fold
enrichment). In total, 105 (51%) miRNA locations are located
within 5 kb either from the start, end, or both (.3-fold
enrichment). Moreover, miRNAs show slightly higher enrichment
in regions where gene start sites are separated from gene end sites
by less than 10 kb (data not shown).
MicroRNAs associated with non-CIS inserts tend to be close to
promoters of RefSeq genes while CIS-associated miRNAs tend to
be distant from promoters. For example, 13 miRNA loci (16
miRNAs) have non-CIS inserts mapped within 10 kb. Out of
these, 9 loci (69%) are located within 10 kb from RefSeq gene
starts, while out of 10 CIS-associated miRNA loci only 4 are less
than 10 kb from RefSeq gene starts. Six CIS-associated miRNA
loci containing 17 miRNAs are located more than 10 kb away
from promoters of RefSeq genes, indicating that the observed
association between miRNAs and CISs is not explained by co-
localization of miRNAs near genes. A similar tendency is observed
for miRNA 5k loci (miRNAs within 5 kb of each other): out of 10
miRNA 5k loci with non-CIS RIS within 5 kb (Table 3), 7 overlap
RefSeq gene starts. Out of 7 miRNA 5k loci with CIS RIS within
5k (Table 2), 3 overlap RefSeq gene starts.
Interestingly, human miRNAs are also enriched around
transcription start or end sites of RefSeq genes. There are 543
annotated miRNAs in the human genome mapped to 474 unique
miRNA precursor locations. Out of these 474 miRNA locations
108 (23%) are located within 5 kb of RefSeq gene transcription
start or/and end sites (2.2-fold enrichment). We merged these 474
locations into 311 miRNA 5k loci by adding 5 kb on each side of
the precursor and then created the base-pair-wise union (OR) of
locations. Out of 311 miRNA 5k loci 92 (30%) overlap either
transcription start or end sites of RefSeq genes, or both. These 92
loci contain 110 (23%) miRNA precursors. It seems that miRNA
loci in the vicinity of transcription start or end sites contain less
miRNA precursors than miRNA loci located farther from genes
(1.2 and 1.7 miRNA precursors per loci, respectively).
CIS-associated miRNAs are conserved and their
human orthologs are located in cancer-associated
regions
CIS-associated miRNAs have some common features. Most (21
out of 22) CIS-associated miRNAs are located outside of RefSeq
protein-coding genes. The exception, mir-135a-1, is located in the
39 UTR of the gene 6230410P16Rik. In contrast, 5 out of 16
miRNAs having non-CIS inserts within 10 kb are located within
RefSeq genes. On average, CIS-associated miRNA loci contain
more miRNAs than non-CIS associated miRNA loci (2.2 and 1.2
miRNA per locus, respectively).
CIS-associated miRNAs tend to be more conserved than
miRNAs associated with non-CIS inserts, both in alignments of
multiple vertebrate species and in human and mouse pairwise
comparisons. First, we used pre-calculated phastCons [24]
conservation scores based on 17 vertebrates for whole miRNA
precursor sequences. The average conservation score for 22 CIS-
associated miRNA is 0.941 versus 0.739 for 16 non-CIS-associated
miRNA (see Materials and Methods for details). Second, we
compared the sequence identity between mouse miRNA pre-
cursors and their orthologous human sequences. CIS-associated
mouse miRNA precursors have 96% identity with human
sequences whereas non-CIS-associated miRNAs display 91%
identity, slightly lower than the average identity level for all
mouse miRNA precursors (92%). In addition, CIS-associated
miRNA precursors have significantly less indels between mouse
and human sequences.
Considering the high conservation of CIS-associated miRNAs
we looked for the involvement of human homologs in cancer
development. Human homologs of eight CIS-associated miRNA
loci are located in fragile regions and regions involved in cancer
[7] (Table 1). It has been shown that miRNAs are generally
down-regulated in cancer [8]. We therefore compared the
available data on tissue-specific expression of human miRNAs
[25] and the type of cancer associated with the CISs (blood or
brain cancer) located in the vicinity of homologous murine
miRNAs. Eight CIS-associated miRNA loci are co-localized
with insertions determined from various types of blood cancer
(Table 1). Human expression data in 24 different human organs
and cell types was available for orthologs of members of 7 these
loci [25]. There is a high correspondence between the miRNA
expression pattern and the type of cancer induced by retroviral
insertion near these miRNAs. Five loci have human miRNA
orthologs whose expression is highest in tissues associated with
blood development such as bone marrow or thymus. Another
Table 4. Bootstrap analysis for co-localization between non-CIS inserts separated by more than 3 kb and miRNAs.
..................................................................................................................................................
Distance,
kb
MiRNA
loci, #
Observed
# loci
Enrichment,
Fold
Bootstrap (10
7 iterations)
PM a x
5 245 7 2.4 0.027 16
10 237 10 1.9 0.046 20
20 233 22 2.2 0.00058 30
30 228 29 2.0 0.00029 37
See Table 2 for description of the columns.
doi:10.1371/journal.pone.0001133.t004
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PLoS ONE | www.plosone.org 5 November 2007 | Issue 11 | e1133miRNA, miR-22, is enriched in thymus although it is most
abundant in skeletal muscles [25].
DISCUSSION
Here we demonstrate that murine miRNAs are associated with
CISs. The enrichment of miRNAs loci in proximity to CIS inserts is
higher than the enrichment of miRNAs around non-clustered
retroviral insertions located outside of CISs. All but one CIS-
associated miRNA are located outside RefSeq genes and some of
them may be classified as proto-oncogenes or tumor-suppressor
genes. Indeed, the well-characterized oncogenic miRNA cluster mir-
17-92 [9,26] is associated with CIS inserts (Table 1). Ectopic
expression of the mir-17–92 cluster accelerates tumor development
in a mouse B-cell lymphoma model [9]. Another example is the mir-
106a miRNA cistron which shows numerous retroviral integrations
in a lymphocyte tumor screen: tumors containing inserts close to the
mir-106a miRNA cluster exhibit up to a 20-fold higher expression of
these miRNAs [27]. There is also some evidence of the involvement
of mir-142 in cancer development [28].
Formally, we cannot exclude the possibility that insertions affect
(distant) regulatory elements situated in cis to protein-coding genes,
especially when the CISs occur relatively close to genes, e.g., in
HOX clusters (Fig. 1c). However, an equally if not more plausible
explanation is that retroviral insertions are causing changes in the
expression of miRNA genes, especially in those cases where the
insertions occur in close proximity to miRNAs, rather than
affecting more distant protein-coding genes. For example, all five
CIS insertions in region XqA5 are less than 5 kb from the three
miRNAs listed but more than 120 kb from the assigned RIS gene
Gpc3, and four out of seven CIS insertions in region 11qC are
closer to mir-142 than to the nearest assigned gene Supt4h2.I ti s
also possible that that (some) miRNA genes have chromatin
structure open to retroviral integration similar to promoter regions
of protein coding genes. The CIS-associated miRNAs represent
prospective candidates for further experimental studies in the
context of cancer association.
It appears that miRNAs are enriched around the transcription
start and/or end sites of protein-coding genes both in human and
mouse. Considering the strong bias of MLV integrations around
promoter regions [23] it is possible to speculate that the observed
enrichment of non-CIS retroviral insertions near miRNAs may be
at least partially due to the preferential location of miRNAs
around promoter regions. Interestingly, miRNAs located close to
transcription start or end sites tend to be non-clustered indicating
a different type of organization of these miRNA genes.
MATERIALS AND METHODS
We used miRBase release 9.0 (October 2006) which contains 373
mouse miRNAs, 363 of which were mapped to 381 locations
within the Mouse Feb 2006 (mm8) genome assembly (Build 36
‘‘essentially complete’’ assembly by NCBI).
The July 2006 version of the Retroviral Tagged Cancer Gene
Database (RTCGD, http://rtcgd.ncifcrf.gov) [19] contains 2373
retroviral integration sites classified as belonging to Common
Integration Sites (CISs), and 3119 retroviral integration sites
classified as located outside of CISs.
All analysis was done on a local mirror of the UCSC Genome
Browser [20].
Bootstrap analysis was done similarly to [29]. Briefly, miRNAs
were merged into miRNA loci by adding 5, 10, 20 or 30 kb on
each side with subsequent base-pair-wise union (OR) on the
UCSC Genome Browser. The resulting loci were randomly placed
on the mouse genome with mapped CIS inserts or inserts outside
of CISs and any cases of overlap were counted. Genome assembly
gaps were removed from the analysis. Overlaps between randomly
placed loci were prohibited. For each bootstrap test we performed
10
7 iterations.
The conservation of mouse miRNAs was estimated using
phastCons conservation scores [24] for whole miRNA precursors.
The phastCons conservation scores were based on mouse-centric
alignments of 17 species and were obtained from the UCSC
genome browser [20]. The average phastCons score for bases
within each known miRNA was calculated using the UCSC
hgWiggle utility and the -doStats flag. Mouse-human base-pair
identity scores were calculated using pairwise genome alignments
obtained from the UCSC genome browser and the UCSC utilities
axtAndBed and axtCalcMatrix.
The enrichment of miRNAs around transcription start or end
sites was calculated as follows: all RefSeq gene transcription start
and end sites were extracted from the genome browser.
Annotations were created by adding 5 or 10 kb to every
transcription start or end site. The enrichment was calculated as
the ratio between the fraction of miRNAs overlapping these
annotations and the fraction of the genome occupied by the
corresponding annotations.
The linear and logarithmic trendlines and R2 values were
calculated using Microsoft Excel 2003. The linear trendline for
miRNAs associated with non-CIS inserts was described by
y=1.2286x+6.3333 with R
2=0.9396. The linear trendline for
miRNAs associated with CIS inserts was described by
y=0.3371x+17.6 and R
2=0.7831. The logarithmic trendline for
miRNAs associated with CIS inserts was described by
y=5.2282Ln(x)+9.3527 with R
2=0.945.
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